Checkpoint Capital L.P.
In its 13F for Q3 2024 (holdings as of September 30, 2024, filed November 14, 2024), Checkpoint Capital L.P. reported 16 stock positions worth $201.6 million. Its top holding was Argenx SE - ADR (ARGX) at 24.9% of the portfolio, followed by Rhythm Pharmaceuticals (RYTM, 17.2%) and Phathom Pharmaceuticals (PHAT, 13.5%). Compared with Q2 2024, it opened 3 new positions, sold out of 3, added to 6 and reduced 6. The biggest buy was Phathom Pharmaceuticals (PHAT, shares +72%) and the biggest sale Rhythm Pharmaceuticals (RYTM, shares −28%).
- Most Recent 13F
- Q2 2026
- Location
- SAN FRANCISCO, CA
- CIK
- 0001977548
- Portfolio Value
- $201.6M (Q3 2024)
- SEC Filing
- 0001977548-24-000008 ↗ filed Nov 14, 2024
Holdings Value
Holdings 16 stocks · $201.6M
| ARGX Argenx SE - ADR | 24.88% | 92,500 | $50.1M | Add +12.6% |
| RYTM Rhythm Pharmaceuticals Inc. | 17.24% | 663,381 | $34.8M | Reduce -28.1% |
| PHAT Phathom Pharmaceuticals Inc. | 13.49% | 1,504,307 | $27.2M | Add +71.9% |
| CYTK Cytokinetics Inc. | 12.23% | 466,813 | $24.6M | Add +145.7% |
| AXSM Axsome Therapeutics Inc. | 9.35% | 209,632 | $18.8M | Reduce -27.9% |
| AVDL Avadel Pharmaceuticals Ltd. | 7.16% | 1,100,000 | $14.4M | Reduce -3.4% |
| PTGX Protagonist Therapeutics Inc. | 5.36% | 240,000 | $10.8M | Reduce -32.4% |
| PLRX Pliant Therapeutics Inc. | 2.11% | 380,000 | $4.3M | Add +63.6% |
| TCRX Tscan Therapeutics Inc. | 2.04% | 825,341 | $4.1M | New |
| ATYR Atyr Pharma Inc. | 1.52% | 1,736,477 | $3.1M | Reduce -10.8% |
| SLNO Soleno Therapeutics Inc. | 1.45% | 57,983 | $2.9M | Add +194.4% |
| CDTX Cidara Therapeutics Inc. | 0.97% | 182,426 | $2.0M | Add +25.4% |
| STOK Stoke Therapeutics Inc. | 0.96% | 157,514 | $1.9M | New |
| IRON Disc Medicine Inc. | 0.62% | 25,543 | $1.3M | New |
| TRVI Trevi Therapeutics Inc. | 0.41% | 250,000 | $835K | Reduce -50.0% |
| ALLK Allakos LLC | 0.21% | 649,957 | $425K | No change |
Portfolio Sells Q2 2024 → Q3 2024
| RYTM Rhythm Pharmaceuticals Inc. | Reduce -28.1% | 17.24% | −5.58 |
| CORT Corcept Therapeutics Inc. | Sold out | 0.00% | −4.79 |
| AXSM Axsome Therapeutics Inc. | Reduce -27.9% | 9.35% | −4.76 |
| AVDL Avadel Pharmaceuticals Ltd. | Reduce -3.4% | 7.16% | −2.49 |
| PTGX Protagonist Therapeutics Inc. | Reduce -32.4% | 5.36% | −2.06 |
| KYMR Kymera Therapeutics Inc. | Sold out | 0.00% | −1.48 |
| APLT Applied Therapeutics Inc. | Sold out | 0.00% | −0.64 |
| TRVI Trevi Therapeutics Inc. | Reduce -50.0% | 0.41% | −0.48 |
| ATYR Atyr Pharma Inc. | Reduce -10.8% | 1.52% | −0.31 |
Portfolio Buys Q2 2024 → Q3 2024
| PHAT Phathom Pharmaceuticals Inc. | Add +71.9% | 13.49% | +8.06 |
| CYTK Cytokinetics Inc. | Add +145.7% | 12.23% | +6.02 |
| ARGX Argenx SE - ADR | Add +12.6% | 24.88% | +3.58 |
| TCRX Tscan Therapeutics Inc. | New | 2.04% | +2.04 |
| SLNO Soleno Therapeutics Inc. | Add +194.4% | 1.45% | +0.97 |
| STOK Stoke Therapeutics Inc. | New | 0.96% | +0.96 |
| IRON Disc Medicine Inc. | New | 0.62% | +0.62 |
| PLRX Pliant Therapeutics Inc. | Add +63.6% | 2.11% | +0.61 |
| CDTX Cidara Therapeutics Inc. | Add +25.4% | 0.97% | −0.07 |
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 6 | $389.8M | RYTM, ARGX, RVMD, CYTK, IRON |
| Q1 2026 | 8 | $278.7M | ARGX, RYTM, RVMD, IRON, CYTK |
| Q4 2025 | 6 | $315.6M | ARGX, RYTM, IRON, RVMD, CORT |
| Q3 2025 | 10 | $298.5M | ARGX, RYTM, CORT, IRON, RVMD |
| Q2 2025 | 8 | $214.6M | ARGX, RYTM, CORT, IRON, RVMD |
| Q1 2025 | 14 | $182.3M | ARGX, RYTM, RVMD, SLNO, IRON |
| Q4 2024 | 16 | $196.5M | ARGX, RYTM, PHAT, AXSM, IRON |
| Q3 2024 | 16 | $201.6M | ARGX, RYTM, PHAT, CYTK, AXSM |
| Q2 2024 | 16 | $165.9M | RYTM, ARGX, AXSM, AVDL, PTGX |
| Q1 2024 | 17 | $149.6M | RYTM, ARGX, CYTK, AVDL, AXSM |